Ionis Pharmaceuticals IONS Commercial — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's commercial — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's commercial — revenue?
- Ionis Pharmaceuticals (IONS) reported commercial — revenue of $107.81M in Q1 2026.
- How has Ionis Pharmaceuticals's commercial — revenue changed year-over-year?
- Ionis Pharmaceuticals's commercial — revenue increased by 41.5% year-over-year, from $76.17M to $107.81M.
- What is the long-term trend for Ionis Pharmaceuticals's commercial — revenue?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's commercial — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $342.4M to $435.85M.
- What does commercial — revenue mean?
- The total revenue earned from selling commercial pharmaceutical products to customers.
- How do you interpret commercial — revenue?
- An increase indicates successful market adoption and growing demand for the company's commercialized drug portfolio. A decrease may signal increased competition, patent expirations, or challenges in market access and reimbursement.
- How does commercial — revenue compare across companies?
- Comparable to net product sales reported by other biotechnology and pharmaceutical companies, excluding milestone payments or royalty income.